DEBIOPHARM AND DEVELOGEN ANNOUNCE PARTNERING OF MYASTHENIA GRAVIS PROGRAM

Debiopharm S.A., the independent drug development company specialising in oncology, endocrinology and niche products and DeveloGen AG, a biopharmaceutical company focusing on novel treatments for metabolic disorders, today announced an exclusive worldwide collaboration and licensing agreement, by which Debiopharm will develop PTR-262, a novel peptide drug for the treatment of myasthenia gravis (MG), before out-licensing to global partners for commercialisation.

Yahoo News (http://biz.yahoo.com/prnews/050816/uktu003.html?.v=24)